(Q35978082)

English

A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 August 2017

A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma (English)

1 reference

Europe PubMed Central

11 August 2017

author name string

Lissoni P

1

1 reference

Europe PubMed Central

11 August 2017

Barni S

2

1 reference

Europe PubMed Central

11 August 2017

Tancini G

3

1 reference

Europe PubMed Central

11 August 2017

Ardizzoia A

4

1 reference

Europe PubMed Central

11 August 2017

Ricci G

5

1 reference

Europe PubMed Central

11 August 2017

Aldeghi R

6

1 reference

Europe PubMed Central

11 August 2017

Brivio F

7

1 reference

Europe PubMed Central

11 August 2017

Tisi E

8

1 reference

Europe PubMed Central

11 August 2017

Rovelli F

9

1 reference

Europe PubMed Central

11 August 2017

Rescaldani R

10

1 reference

Europe PubMed Central

11 August 2017

language of work or name

0 references

publication date

1 January 1994

1 reference

Europe PubMed Central

11 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

11 August 2017

69

1 reference

Europe PubMed Central

11 August 2017

1

1 reference

Europe PubMed Central

11 August 2017

196-199

1 reference

Europe PubMed Central

11 August 2017

https://scigraph.springernature.com/pub.10.1038/bjc.1994.34

0 references

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968792

2 October 2017

Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968792

2 October 2017

The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2 [corrected]

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968792

2 October 2017

Suppressor Cells in Neoplastic Disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968792

2 October 2017

Circadian variation of lymphocyte subpopulations: a study with monoclonal antibodies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968792

11 July 2018

Role of the pineal gland in immunity. Circadian synthesis and release of melatonin modulates the antibody response and antagonizes the immunosuppressive effect of corticosterone.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968792

11 July 2018

The neuroendocrine effects of interleukin-2 treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968792

11 July 2018

Endocrine effects of a 24-hour intravenous infusion of interleukin-2 in the immunotherapy of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968792

11 July 2018

Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968792

11 July 2018

Immunological effects of a single evening subcutaneous injection of low-dose interleukin-2 in association with the pineal hormone melatonin in advanced cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968792

11 July 2018

Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968792

24 September 2018

Continuous infusion recombinant interleukin-2 (rIL-2) in adoptive cellular therapy of renal carcinoma and other malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/8286206

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results

1 reference

https://pubmed.ncbi.nlm.nih.gov/8286206

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.1994.34

1 reference

Europe PubMed Central

11 August 2017

1 reference

Europe PubMed Central

11 August 2017

1 reference

Europe PubMed Central

11 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35978082&oldid=1966650504"